Health Economics›Cutaneous squamous cell carcinoma›Advanced or metastatic disease all lines of therapy

Advanced or metastatic disease all lines of therapy

Cutaneous squamous cell carcinoma · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~5.3 mo	~32.7 mo	~2	~R 573 911 PFS proxy · indirect	12
Cetuximab monotherapy Variant #07	—	R 11 811	180d	—	~7.5 mo	~2	~R 23 621 PFS proxy · indirect	6
Cisplatin and Doxorubicin Variant #01	—	R 1 434	21d	~5.7 mo	~12.3 mo	~4	~R 5 734 PFS proxy · indirect	4
Cisplatin, Interferon alfa-2a, Isotretinoin Variant #01 Partial	—	R 397	7d	—	—	~2	~R 794 indirect	—
Cemiplimab monotherapy Variant #01 Partial	—	—	21d	~10.3 mo	~19.1 mo	~48	—	7

5 of 5 regimens shown